Not exact matches
Spark Therapeutics» stock soared 20 % in Wednesday trading
on the heels of its second quarter 2017 earnings report and some (very) early data
on the
gene therapy - focused firm's
treatment for the blood disorder hemophilia A.
That means the
treatment could be approved
on or before January 12, 2018, which would make it the first - ever
gene therapy cleared to treat a genetic condition in the U.S..
AveXis, Inc., a clinical - stage
gene therapy company developing treatments for patients suffering from rare and life - threatening neurological genetic diseases, announced in July 2016 that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the treatment based on preliminary clinical results from the trial of AVXS
therapy company developing
treatments for patients suffering from rare and life - threatening neurological genetic diseases, announced in July 2016 that the U.S. Food and Drug Administration (FDA) granted Breakthrough
Therapy Designation for the treatment based on preliminary clinical results from the trial of AVXS
Therapy Designation for the
treatment based
on preliminary clinical results from the trial of AVXS - 101.
These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of
gene therapy, despite some setbacks; continuing progress in research
on stem cells; the emergence of
treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.
This type of
treatment is what we call
gene therapy and researchers have been working
on developing techniques to accomplish this for many years.
Tsigelny added: «The clinical
treatments that do not take into consideration the specific mutations in
genes, but rather treat all mutations within a specific
gene such as EGFR as the same, are a «hit - or - miss» game because they are based solely
on observational data
on how other patients previously have reacted to drug
therapies.»
Based
on these promising results, work has begun
on the necessary developments to propose to patients suffering from Friedreich's ataxia and presenting a progressive cardiomyopathy a
treatment by
gene therapy.
Although
gene therapy has since proved successful against rare diseases of the immune system and shown promise against AIDS (see «Genetic
treatment closes door
on HIV»), it has proved much harder to use it to treat CF.
LONDON (Reuters)- The science of
gene therapy is finally delivering
on its potential, and drugmakers are now hoping to produce commercially viable medicines after tiny sales for the first two such
treatments in Europe.
Under the proposed law,
gene therapy will be approved only for the
treatment of people with genetic diseases such as cystic fibrosis and will not be allowed in germ cells, where genetic alterations would be passed
on to the next generation.
According to Saura, «this study opens up new perspectives
on therapeutic prevention and
treatment of Alzheimer's disease, given that we have demonstrated that a
gene therapy which activates the Crtc1 protein is effective in preventing the loss of memory in lab mice».
Dr. Giatsidis and coauthors reviewed the state of the art in research
on gene therapy techniques for
treatment of local disorders and injuries — the first such review in more than a decade.
Gene Therapy Approaches Studied for «Almost Every Tissue»... Dr. Giatsidis and coauthors reviewed the state of the art in research on gene therapy techniques for treatment of local disorders and injuries — the first such review in more than a dec
Gene Therapy Approaches Studied for «Almost Every Tissue»... Dr. Giatsidis and coauthors reviewed the state of the art in research on gene therapy techniques for treatment of local disorders and injuries — the first such review in more than a
Therapy Approaches Studied for «Almost Every Tissue»... Dr. Giatsidis and coauthors reviewed the state of the art in research
on gene therapy techniques for treatment of local disorders and injuries — the first such review in more than a dec
gene therapy techniques for treatment of local disorders and injuries — the first such review in more than a
therapy techniques for
treatment of local disorders and injuries — the first such review in more than a decade.
This specificity in
treatment fits with an emerging approach in cancer
treatment nationwide, known as personalized medicine, in which the
therapies for each patient are selected based
on the
genes altered in their tumors.
When tested
on mice that already had the disease, the
treatment significantly reversed the symptoms just eight days after the
gene therapy was delivered.
Paris, France, April 3, 2018, 5.35 pm CET — GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA - PME eligible), a biopharma company focused
on discovering and developing innovative
gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced topline results from the REVERSE Phase III clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2 / 2 - ND 4) in 37 subjects whose visual loss due to 11778 - ND4 Leber Hereditary Optic Neuropathy (LHON) commenced between 6 and 12 months prior to study
treatment.
A significant percentage of children and young adults with
treatment - resistant B - cell leukemia achieved remission through a new CAR T - cell
gene therapy that destroys cancer cells with the CD22 molecule
on its surface.
The FDA has signed off
on Ultragenyx Pharmaceutical's (RARE -1.1 %) IND for
gene therapy DTX401 for the potential
treatment of glycogen storage...
Clinical research activities are focused
on the implementation of experimental protocols based
on gene or cell
therapy for the
treatment of genetic blood disorders such as ADA - SCID, Wiskott - Aldrich Syndrome, Metachromatic Leukodystrophy, Beta - thalassemia, Chronic granulomatous disease, Mucopolysaccharidosis Type I (Hurler).
This work, published in «Blood», was carried out by the CNIO Telomeres and Telomerase Group The
treatment is based
on the transport of the telomerase
gene to the bone marrow cells using
gene therapy, a completely new strategy in the
treatment of aplastic anaemia
«
Gene therapy, or any treatment that relies on tight regulation of gene expression, could be improved by precisely targeting molecules to the right place in the nucleus,» says Kar
Gene therapy, or any
treatment that relies
on tight regulation of
gene expression, could be improved by precisely targeting molecules to the right place in the nucleus,» says Kar
gene expression, could be improved by precisely targeting molecules to the right place in the nucleus,» says Karpen.
Up to 50 million Americans are estimated to have an autoimmune condition, * and annual direct healthcare
treatment costs for these patients total $ 100 billion.1 Nearly 100 different diseases have been classified as autoimmune in nature, with 40 more suspected.1 IFM's 2018 Annual International Conference (AIC), «Solving the Puzzle of Autoimmunity: The Interplay of Gut,
Genes, and Environment,» focuses
on the exploding research and
therapies around the interconnected roles of intestinal permeability, genetic disruptors, and various environmental triggers that coalesce to create autoimmune disease.
Auburn University College of Veterinary Medicine, UMass Medical School to test
gene therapy treatment for Tay - Sachs and Sandhoff diseases Researchers at Auburn University College of Veterinary Medicine and UMass Medical School are nearing human clinical trials
on a genetic
therapy for two rare neurological diseases that are fatal to children.
Research done
on cartilage transplantation and
gene cell
therapy in the Orthopaedics Laboratory has been utilized in the
treatment of knee injuries in people.
«We look forward to helping the company realize the tremendous promise of its
gene therapy platform, which has the potential to provide patients suffering from these severe eye diseases with
treatments that offer life - long clinical benefits, potentially based
on a one - time therapeutic administration.»